NASDAQ:CFMSConforMIS Stock Price, Forecast & News

ConforMIS's stock was trading at $0.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CFMS stock has increased by 13.6% and is now trading at $0.7495.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ConforMIS.

ConforMIS Inc (NASDAQ:CFMS) released its quarterly earnings results on Wednesday, August, 5th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.04. ConforMIS had a negative net margin of 41.29% and a negative return on equity of 165.61%.
View ConforMIS's earnings history.

ConforMIS issued an update on its second quarter 2020 Pre-Market earnings guidance on Monday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $19.5-19.5 million, compared to the consensus revenue estimate of $4.84 million.

4 brokerages have issued 12-month price objectives for ConforMIS's stock. Their forecasts range from $2.00 to $3.00. On average, they expect ConforMIS's stock price to reach $2.33 in the next year. This suggests a possible upside of 211.3% from the stock's current price.
View analysts' price targets for ConforMIS.

News stories about CFMS stock have been trending neutral on Thursday, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ConforMIS earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about ConforMIS.

ConforMIS saw a drop in short interest in July. As of July 15th, there was short interest totaling 874,100 shares, a drop of 36.7% from the June 30th total of 1,380,000 shares. Based on an average daily trading volume, of 703,300 shares, the short-interest ratio is currently 1.2 days. Currently, 1.4% of the shares of the company are sold short.
View ConforMIS's Current Options Chain.

Some companies that are related to ConforMIS include Lakeland Industries (LAKE), Sientra (SIEN), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Allied Healthcare Products (AHPI), Ocugen (OCGN), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), NanoVibronix (NAOV), Bionik Laboratories (BNKL) and Avitar (AVTI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Advanced Micro Devices (AMD), Alibaba Group (BABA), AbbVie (ABBV), Pfizer (PFE) and Starbucks (SBUX).

(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

ConforMIS's stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.90%) and Bourgeon Capital Management LLC (0.05%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, Erin Henry, J Brent Alldredge, Mark A Augusti, Patricia A Davis and Paul S Weiner.
View institutional ownership trends for ConforMIS.

CFMS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold ConforMIS company stock in the last year include Erin Henry, J Brent Alldredge, Mark A Augusti, and Paul S Weiner.
View insider buying and selling activity for ConforMIS.

CFMS stock was purchased by a variety of institutional investors in the last quarter, including Bourgeon Capital Management LLC.
View insider buying and selling activity for ConforMIS.

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CFMS stock can currently be purchased for approximately $0.75.

ConforMIS has a market capitalization of $53.57 million and generates $77.43 million in revenue each year. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. ConforMIS employs 262 workers across the globe.

The official website for ConforMIS is www.conformis.com.

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]